Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/14/24
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's LymphomaGlobeNewsWire • 08/12/24
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/15/24
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic MalignanciesGlobeNewsWire • 04/08/24
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceGlobeNewsWire • 03/22/24
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601GlobeNewsWire • 01/22/24
Marker Therapeutics Announces Clinical Program Updates and Pipeline PrioritizationGlobeNewsWire • 01/08/24
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”GlobeNewsWire • 12/21/23
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseGlobeNewsWire • 09/11/23
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/30/23
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell TherapiesNewsfile Corp • 08/17/23
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/23
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf ProgramGlobeNewsWire • 08/07/23
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML PatientsGlobeNewsWire • 07/10/23
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent AdministrationGlobeNewsWire • 06/26/23
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical TrialGlobeNewsWire • 06/12/23
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsGlobeNewsWire • 05/31/23
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™GlobeNewsWire • 05/01/23